857167-91-0

Basic information

• Product Name: 2-(4-(phenylethynyl)phenyl)acetic acid
• Synonyms: 2-(4-(phenylethynyl)phenyl)acetic acid
• CAS NO: 857167-91-0
• Molecular Weight: 236.27
• Mol File: 857167-91-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-(4-(phenylethynyl)phenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-(phenylethynyl)phenyl)acetic acid(857167-91-0)
• EPA Substance Registry System: 2-(4-(phenylethynyl)phenyl)acetic acid(857167-91-0)

Safety Data

• Hazardous Substances Data: 857167-91-0(Hazardous Substances Data)

Upstream product

• 92866-00-7 4-ethynyltolane 
• 536-74-3 phenylacetylene 
• 1323987-20-7 ethyl 2-(4-(phenylethynyl)phenyl)acetate 
• 32555-96-7 4-stilbenecarboxaldehyde 
• 100865-20-1 Stilben-aldehyd-⁽⁴⁾-dibromid 
• 25851-08-5 4-(phenylethynyl)benzoyl chloride 
• 25739-23-5 4-(phenylethynyl)benzoic acid 
• 860217-52-3 Tolan-essigsaeure-⁽⁴⁾-amid 

Downstream Products

• 42196-54-3 trans-Bis-(p-phenylethinyl)-stilben 

Relevant articles and documents

Oxidation of Alkynyl Boronates to Carboxylic Acids, Esters, and Amides

A general efficient protocol was developed for the synthesis of carboxylic acids, esters, and amides through oxidation of alkynyl boronates, generated directly from terminal alkynes. This protocol represents the first example of C(sp)?B bond oxidation. This approach displays a broad substrate scope, including aryl and alkyl alkynes, and exhibits excellent functional group tolerance. Water, primary and secondary alcohols, and amines are suitable nucleophiles for this transformation. Notably, amino acids and peptides can be used as nucleophiles, providing an efficient method for the synthesis and modification of peptides. The practicability of this methodology was further highlighted by the preparation of pharmaceutical molecules.

Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability

The free fatty acid receptor 1 (FFA1, also known as GPR40) mediates enhancement of glucose-stimulated insulin secretion and is emerging as a new target for the treatment of type 2 diabetes. Several FFA1 agonists are known, but the majority of these suffer from high lipophilicity. We have previously reported the FFA1 agonist 3 (TUG-424). We here describe the continued structure-activity exploration and optimization of this compound series, leading to the discovery of the more potent agonist 40, a compound with low lipophilicity, excellent in vitro metabolic stability and permeability, complete oral bioavailability, and appreciable efficacy on glucose tolerance in mice.